Search Results
Feb 13, 2026, 11:00 ET Open Pontoon Boat Market Poised for Steady Expansion from USD 1.5 Billion in 2024 to USD 2.3 Billion by 2033, Supported by Rising Recreational Boating Demand : - Market Research Intellect
II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology Applications, Neuromuscular
More news about: Market Research Intellect
Feb 13, 2026, 10:39 ET Electronic Discovery Software Market to Reach USD 10.1 Billion by 2033, Fueled by Rising Digital Litigation, Regulatory Compliance Needs, and Advanced Analytics Adoption: Market Research Intellect
II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology Applications, Neuromuscular
More news about: Market Research Intellect
Feb 13, 2026, 10:30 ET Cleanroom Technologies Market worth $ 12.93 billion by 2031 | MarketsandMarkets™
because of the global standards that have become stricter, like EU GMP Annex 1, revisions to ISO 14644, and increasing FDA scrutiny. Biologics, cell and gene therapies, vaccines, and high-potency APIs require ultra-sterile manufacturing environments, which in turn increase the demand for high-performance
More news about: MarketsandMarkets
Feb 13, 2026, 08:27 ET Ecovyst to Host Fourth Quarter 2025 Earnings Conference Call and Webcast on Thursday, February 26, 2026 at 11:00 a.m. ET
https://www.ecovyst.com.Investor Contact:Gene Shiels(484) 617 [email protected]
More news about: Ecovyst Inc.
Feb 13, 2026, 07:00 ET Insmed To Present at March 2026 Investor Conferences
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey,
More news about: Insmed Incorporated
Feb 13, 2026, 02:28 ET World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors
survival by two- to three-fold. In some animals, tumors were completely eliminated with long-term, recurrence-free outcomes.By using exosomes as a gene and drug delivery vehicle, EXO 001 achieves higher biocompatibility and safety compared with viral vectors or synthetic lipid materials. This approach
More news about: China Medical University Hospital
Feb 12, 2026, 19:00 ET Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
clinical proportion of HER2-positive breast cancer is approximately 20%[1]. Previous studies have demonstrated that overexpression of this HER2 gene plays a significant role in the occurrence and development of invasive breast cancer and is associated with an increased recurrence rate and poor prognosis
More news about: Innovent Biologics
Feb 12, 2026, 18:51 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
2026, Regenxbio issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Pomerantz LLP
Feb 12, 2026, 14:15 ET Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V. (QURE) - Contact Kessler Topaz Meltzer & Check, LLP
biotechnology company developing gene therapies for rare diseases, including Huntington's disease ("HD"). uniQure is incorporated in The Netherlands with its principal executive offices in Amsterdam, The Netherlands.The Company's leading drug candidate is AMT-130, a novel gene therapy being developed
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 12, 2026, 10:15 ET Leukapheresis Market worth $138.7 million by 2031 | MarketsandMarkets™
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20283148 The global leukapheresis market is witnessing steady growth due to several concerns, like increasing cases of leukemia, the quick ramp-up of cell and gene therapy programs, and broader use of leukapheresis as the vital first step in both autologous and allogeneic cell therapy manufacturing. A notable rise
More news about: MarketsandMarkets
Feb 12, 2026, 09:00 ET Devonian reports additional molecular data from MASH liver study
observed across gene categories, consistent with a pharmacologically driven effect. In addition, gene expression analysis revealed key differences between the caudal and lateral liver lobes, indicating regional variation in Thykamine™'s molecular activity within the diseased liver.Gene expression analysis
More news about: Devonian Health Group Inc.
Feb 12, 2026, 08:33 ET Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases
critical component of the high-affinity IgE receptor pathway central to allergic disease activationModulation of MS4A6A, a gene associated with immune signaling and inflammatory regulationCombination therapeutic strategies designed to reduce hypersensitivity
More news about: Hoth Therapeutics, Inc.
Feb 12, 2026, 08:03 ET BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market
tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain cytokine and growth factor products manufactured by Qkine for use in cell and gene therapy manufacturing.
More news about: BioLife Solutions, Inc.
Feb 12, 2026, 08:00 ET Apertura Gene Therapy Launches Open Aperture, a Material Transfer Agreement Program to Facilitate Non-Commercial Access to TfR1 CapX for Academic Researchers
Science.About Apertura Gene TherapyApertura Gene Therapy develops genetic medicines and next-generation AAV capsids that precisely engage human-relevant receptors, aiming to enable more effective and selective gene delivery. The company's lead capsid, TfR1 CapX, leverages
More news about: Apertura Gene Therapy
Feb 12, 2026, 08:00 ET Immunexpress Announces Publication Showing SeptiCyte RAPID® Identifies Septic Patients Most Likely to Have Positive Blood Cultures
for patients with suspected sepsis. The company's SeptiCyte® technology assesses a patient's dysregulated immune response by quantifying gene expression from whole blood, delivering actionable information during the critical early hours of sepsis evaluation. By enabling earlier and more confident
More news about: Immunexpress, Inc.
Feb 12, 2026, 07:30 ET Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
delayed menopause.5 TP53 is a well-recognized prognostic marker for EC; >50% of advanced or recurrent EC tumors are TP53wt (gene for tumor protein P53; wild-type), and ~40%-55% are both TP53wt and mismatch repair-proficient (pMMR).6-8 While immune checkpoint
More news about: Karyopharm Therapeutics Inc.
Feb 12, 2026, 05:47 ET Ribo und Ribocure geben exklusive globale Lizenzvereinbarung mit Madrigal für neuartige siRNA-Therapeutika gegen MASH bekannt
der Zusammenarbeit auf neue siRNA-Programme auszuweiten, darunter bispezifische siRNAs (Wirkstoffe, die gleichzeitig auf zwei krankheitsverursachende Gene abzielen), wobei die einzigartigen GalSTARTM- und siRNA-Plattformen für chemische Modifikationen von Ribo zum Einsatz kommen.Wir
More news about: Suzhou Ribo Life Science Co., Ltd.
Feb 11, 2026, 20:00 ET ToolGen Enters 'Harvest Season' for Global IP Monetization; Appoints Litigation & Negotiation Expert Dave Koo as CLO
SEOUL, South Korea, Feb. 11, 2026 /PRNewswire/ -- ToolGen (CEO Jong-sang Ryu), a leader in gene-editing technology, announced the appointment of Dave Boncheun Koo, a U.S. attorney and renowned expert in international litigation and negotiation,
More news about: ToolGen
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
Sutetinib, Izalontamab Brengitecan (BMS-986507), Silevertinib (BDTX-1535), LP-300, and others.Convergence of TKIs, ADCs, bispecifics, CDAC, and gene-therapy combinations signals a densely crowded and competitive future, where differentiation by efficacy, resistance coverage, administration
More news about: DelveInsight Business Research, LLP
Feb 11, 2026, 15:57 ET Jodie Turner-Smith, Rachel Zoe, Ciara Miller, Ming Lee Simmons, Whitney Leavitt, Lana Condor, and More Glow at The Spring Beauty Studio at Target SoHo during NYFW
including:Up Your Aura Touch-Up Bar: Guests experienced elevated touch-ups provided by celebrity makeup artists including Billie Gene and Sierra Matthews, hair stylists Karen Miller and Ryann Carter and stylists Ayumi Perry and Rachel Betancourt. These experts provided quick beauty
More news about: Target Corporation
Feb 11, 2026, 10:50 ET Genomics Market to Reach $97.1 Billion by 2033 Globally, at 11.5% CAGR: Allied Market Research
biomarkers for disease diagnosis and treatment optimization. Functional genomics and epigenomics also contributed notably due to expanding molecular and gene expression research.Want to Explore More, Connect to our Analyst -
More news about: Allied Market Research
Feb 11, 2026, 10:05 ET 15 Innovators to be Inducted as the National Inventors Hall of Fame Class of 2026
businesses. He is the co-founder of Broadcom Inc., a global leader in wired and wireless communications.Feng Zhang: CRISPR Gene EditingFeng Zhang has invented transformative technologies to improve human health, including first demonstrating the use of engineered
More news about: National Inventors Hall of Fame
Feb 11, 2026, 09:42 ET Takebe Named to TIME100 Health List of Most Influential Leaders
The honor spotlights the 100 most influential innovators, leaders, pioneers, and catalysts who have pushed new ideas ahead—from gene therapies to regulatory agencies—to build healthier populations around the world. Takebe is the first scientist from Cincinnati Children's to be selected
More news about: Cincinnati Children's Hospital Medical Center
Feb 11, 2026, 09:10 ET Dr. Emil Lou, Intima Bioscience Principal Investigator, Named to 2026 TIME100 Health List
leaders in health this year. As the global order has shifted, these titans, innovators, leaders, pioneers, and catalysts have pushed new ideas – from gene therapies to regulatory agencies – ahead to build healthier populations around the world.The full 2026 TIME100 Health list will appear in the
More news about: Intima Bioscience
Feb 11, 2026, 08:57 ET Jeffrey Modell Foundation to Host Renowned Immunologist for Virtual Talk on Gene Therapy for Primary Immunodeficiency
UCLA Professor Donald B. Kohn, MD will speak about gene therapy for Inborn Errors of ImmunityNEW YORK, Feb. 11, 2026 /PRNewswire/ -- On March 25, 2026 the
More news about: Jeffrey Modell Foundation